CN108782459B - 经遗传修饰的非人动物及其使用方法 - Google Patents

经遗传修饰的非人动物及其使用方法 Download PDF

Info

Publication number
CN108782459B
CN108782459B CN201810721840.5A CN201810721840A CN108782459B CN 108782459 B CN108782459 B CN 108782459B CN 201810721840 A CN201810721840 A CN 201810721840A CN 108782459 B CN108782459 B CN 108782459B
Authority
CN
China
Prior art keywords
human
polypeptide
csf
cells
mouse
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201810721840.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN108782459A (zh
Inventor
R·A·弗拉维尔
M·曼茨
A·龙沃
T·施特罗维希
T·维林格
A·J·墨菲
S·史蒂文斯
G·雅克波罗斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute for Research in Biomedicine IRB
Yale University
Regeneron Pharmaceuticals Inc
Original Assignee
Institute for Research in Biomedicine IRB
Yale University
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute for Research in Biomedicine IRB, Yale University, Regeneron Pharmaceuticals Inc filed Critical Institute for Research in Biomedicine IRB
Publication of CN108782459A publication Critical patent/CN108782459A/zh
Application granted granted Critical
Publication of CN108782459B publication Critical patent/CN108782459B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/524—Thrombopoietin, i.e. C-MPL ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5403—IL-3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/12—Animals modified by administration of exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0381—Animal model for diseases of the hematopoietic system
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0387—Animal model for diseases of the immune system

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Environmental Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201810721840.5A 2012-09-07 2013-09-06 经遗传修饰的非人动物及其使用方法 Active CN108782459B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261698002P 2012-09-07 2012-09-07
US61/698,002 2012-09-07
US201361775171P 2013-03-08 2013-03-08
US61/775,171 2013-03-08
CN201380046265.9A CN104955326B (zh) 2012-09-07 2013-09-06 经遗传修饰的非人动物及其使用方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380046265.9A Division CN104955326B (zh) 2012-09-07 2013-09-06 经遗传修饰的非人动物及其使用方法

Publications (2)

Publication Number Publication Date
CN108782459A CN108782459A (zh) 2018-11-13
CN108782459B true CN108782459B (zh) 2021-11-05

Family

ID=50237767

Family Applications (4)

Application Number Title Priority Date Filing Date
CN201810721840.5A Active CN108782459B (zh) 2012-09-07 2013-09-06 经遗传修饰的非人动物及其使用方法
CN202510882358.XA Pending CN120718856A (zh) 2012-09-07 2013-09-06 经遗传修饰的非人动物及其使用方法
CN202111215079.6A Active CN113897398B (zh) 2012-09-07 2013-09-06 经遗传修饰的非人动物及其使用方法
CN201380046265.9A Active CN104955326B (zh) 2012-09-07 2013-09-06 经遗传修饰的非人动物及其使用方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN202510882358.XA Pending CN120718856A (zh) 2012-09-07 2013-09-06 经遗传修饰的非人动物及其使用方法
CN202111215079.6A Active CN113897398B (zh) 2012-09-07 2013-09-06 经遗传修饰的非人动物及其使用方法
CN201380046265.9A Active CN104955326B (zh) 2012-09-07 2013-09-06 经遗传修饰的非人动物及其使用方法

Country Status (18)

Country Link
US (6) US9820476B2 (enExample)
EP (3) EP2892330B1 (enExample)
JP (5) JP6283031B2 (enExample)
KR (7) KR102473555B1 (enExample)
CN (4) CN108782459B (enExample)
AU (3) AU2013312359B8 (enExample)
CA (1) CA2881468C (enExample)
DK (1) DK2892330T3 (enExample)
ES (2) ES3034290T3 (enExample)
FI (1) FI2892330T3 (enExample)
IL (4) IL282472B2 (enExample)
IN (1) IN2015DN02032A (enExample)
MX (2) MX364714B (enExample)
NZ (3) NZ704957A (enExample)
PT (1) PT2892330T (enExample)
RU (2) RU2642319C2 (enExample)
SG (2) SG11201500504RA (enExample)
WO (1) WO2014039782A2 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3010323T3 (en) 2009-10-06 2025-04-02 Regeneron Pharma Genetically modified mice and engraftment
KR102714361B1 (ko) 2011-02-15 2024-10-11 리제너론 파마슈티칼스 인코포레이티드 인간화된 ｍ－ｃｓｆ 마우스
KR102473555B1 (ko) 2012-09-07 2022-12-05 예일 유니버시티 유전적으로 변형된 비-인간 동물 및 이것들의 사용 방법
IL311744B2 (en) * 2012-11-05 2025-10-01 Regeneron Pharma Genetically modified non-human animals and methods of using them
PT4269430T (pt) 2013-09-23 2025-08-06 Regeneron Pharma Animais não-humanos com um gene humanizado de proteína reguladora de sinal
EP3138397B1 (en) 2013-10-15 2018-12-26 Regeneron Pharmaceuticals, Inc. Humanized il-15 animals
EP3071025B1 (en) 2013-11-19 2018-10-10 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized a proliferation-inducing ligand gene
MX2016014504A (es) 2014-05-05 2017-05-23 Regeneron Pharma Animales c5 y c3 humanizados.
NO2785538T3 (enExample) 2014-05-07 2018-08-04
KR20250096864A (ko) 2014-05-19 2025-06-27 리제너론 파마슈티칼스 인코포레이티드 인간 epo를 발현하는 유전자 변형된 비-인간 동물
EP3086637B1 (en) 2014-12-05 2019-01-02 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized cluster of differentiation 47 gene
MX2017007636A (es) 2014-12-09 2018-03-28 Regeneron Pharma Animales no humanos que tienen un gen del grupo de diferenciacion 274 humanizado.
US9888673B2 (en) 2014-12-10 2018-02-13 Regents Of The University Of Minnesota Genetically modified cells, tissues, and organs for treating disease
CN107896479B (zh) * 2015-04-13 2021-07-13 再生元制药公司 人源化SIRPα-IL15敲入小鼠及其使用方法
AU2016358101B2 (en) 2015-11-20 2022-12-01 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized Lymphocyte-activation gene 3
KR102487839B1 (ko) 2016-02-04 2023-01-12 리제너론 파마슈티칼스 인코포레이티드 조작된 angptl8 유전자를 갖는 비인간 동물
SG10202001578RA (en) 2016-02-29 2020-04-29 Regeneron Pharma Rodents having a humanized tmprss gene
CN106119284A (zh) * 2016-06-27 2016-11-16 北京维通达生物技术有限公司 一种用于构建免疫缺陷动物模型的产品及其应用
WO2018102546A1 (en) * 2016-11-30 2018-06-07 The Jackson Laboratory Humanized mouse model with improved human innate immune cell development
RU2019140867A (ru) * 2017-05-12 2021-06-15 Зе Джексон Лаборатори Nsg мыши, не имеющие mhc класса i и класса ii
SMT202400300T1 (it) 2018-07-16 2024-09-16 Regeneron Pharma Modelli di roditori della sindrome ditra e loro utilizzo
WO2020068615A1 (en) * 2018-09-24 2020-04-02 Albert Einstein College Of Medicine Interleukin-8 for maintenance of human acute myeloid leukemia and myelodysplastic syndrome and uses thereof
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN111073907B (zh) * 2018-12-25 2025-07-29 百奥赛图江苏基因生物技术有限公司 人源化细胞因子csf1基因改造非人动物的构建方法及应用
CN111118019B (zh) * 2018-12-25 2021-03-16 百奥赛图江苏基因生物技术有限公司 人源化细胞因子il3基因改造非人动物的构建方法及应用
WO2021011853A2 (en) * 2019-07-17 2021-01-21 Yale University Genetically modified non-human animals and methods of use thereof
CN112779284B (zh) * 2019-11-01 2022-12-20 百奥赛图(北京)医药科技股份有限公司 Thpo基因人源化的非人动物的构建方法及应用
US11339279B2 (en) * 2020-04-01 2022-05-24 Chevron Phillips Chemical Company Lp Dual catalyst system for producing LLDPE and MDPE copolymers with long chain branching for film applications
CN114853871B (zh) * 2021-04-20 2024-04-05 百奥赛图(北京)医药科技股份有限公司 Csf1和/或csf1r基因人源化的非人动物及其构建方法和应用
KR20250040674A (ko) 2022-07-19 2025-03-24 리제너론 파마슈티칼스 인코포레이티드 유전적으로 변형된 동물 모델 및 인간 면역 시스템을 모델링하는데 있어서 그것의 용도
AU2024304358A1 (en) 2023-06-16 2025-11-06 Regeneron Pharmaceuticals, Inc. Vectors, genetically modified cells, and genetically modified non-human animals comprising the same
US20250255282A1 (en) 2024-02-08 2025-08-14 Regeneron Pharmaceuticals, Inc. Vectors, genetically modified cells, and genetically modified non-human animals comprising the same
WO2025212991A1 (en) 2024-04-05 2025-10-09 Regeneron Pharmaceuticals, Inc. Rodent models of disease

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110200982A1 (en) * 2009-10-06 2011-08-18 Regeneron Pharmaceuticals, Inc. Genetically modified mice and engraftment
WO2012040207A2 (en) * 2010-09-20 2012-03-29 Yale University HUMAM SIRPAα TRANSGENIC ANIMALS AND THEIR METHODS OF USE
CN102725400A (zh) * 2009-06-29 2012-10-10 麻省理工学院 制造人源化的非人类哺乳动物的方法

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4736866A (en) 1984-06-22 1988-04-12 President And Fellows Of Harvard College Transgenic non-human mammals
US5573930A (en) 1985-02-05 1996-11-12 Cetus Oncology Corporation DNA encoding various forms of colony stimulating factor-1
HU215241B (hu) 1986-10-24 1998-11-30 Cetus Corp. Eljárás telepstimuláló faktor-1 új formáinak előállítására, valamint az eljárásban alkalmazható expressziós kazetta, vektor és rekombináns gazdasejtek előállítására
ATE119197T1 (de) 1987-12-23 1995-03-15 Univ Leland Stanford Junior Schimäre immunkompromittierende säugetiere und ihre verwendung.
JP2981486B2 (ja) 1988-06-14 1999-11-22 メディカル・バイオロジー・インスティチュート 哺乳動物の免疫系研究方法
EP0438053B1 (en) 1990-01-15 1999-06-16 Yeda Research And Development Company Limited Durable engraftment and development of human hematopoietic lineages in normal mammals
US5849288A (en) 1990-01-15 1998-12-15 Yeda Research And Development Co. Ltd. Method for production of monoclonal antibodies in chimeric mice or rats having xenogeneic antibody-producing cells
US5652373A (en) 1990-01-15 1997-07-29 Yeda Research And Development Co. Ltd. Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems
DE69120890T2 (de) 1990-05-03 1997-02-20 Systemix Inc Menschliches lymph-gewebe in einem wirt mit angegriffenem immunsystem
CA2064075A1 (en) 1990-05-25 1991-11-26 Charles M. Baum Human peripheral blood cells in an immunocompromised host
US5633426A (en) 1990-05-25 1997-05-27 Systemix, Inc. In vivo use of human bone marrow for investigation and production
US5222982A (en) 1991-02-11 1993-06-29 Ommaya Ayub K Spinal fluid driven artificial organ
JPH06505186A (ja) 1991-02-11 1994-06-16 オマーヤ，アユブ　ケー． 脊髄液駆動式人工器官
EP0517199A1 (en) 1991-06-04 1992-12-09 Yeda Research And Development Company, Ltd. Durable engraftment of human tissue and cells in normal mammals
WO1993005796A1 (en) 1991-09-19 1993-04-01 The Scripps Research Institute Method for producing human antibodies in a non-human animal, and animals therefor
EP0539970B1 (en) 1991-10-30 1999-05-26 Idemitsu Kosan Company Limited Methods for producing human lymphocytes and human monoclonal antibodies, and human monoclonal antibodies produced thereby
US6353150B1 (en) 1991-11-22 2002-03-05 Hsc Research And Development Limited Partnership Chimeric mammals with human hematopoietic cells
WO1993018144A1 (en) 1992-03-05 1993-09-16 The Trustees Of Columbia University Of The City Of New York Recombination activating gene deficient animal
US5866757A (en) 1992-06-02 1999-02-02 Yeda Research And Development Co. Ltd. Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems
US6018096A (en) 1993-05-03 2000-01-25 Surrogen, Inc. Animal model for engraftment, proliferation and differentiation of human hematopoietic stem cells
US5663481A (en) 1993-08-06 1997-09-02 Mount Sinai Hospital Corporation Animal model of the human immune system
EP0771348A1 (en) 1994-07-27 1997-05-07 Merck & Co. Inc. Bradykinin b2 receptor modified transgenic non-human animals
US6455756B1 (en) 1994-08-12 2002-09-24 Novartis Ag Long term xenogeneic myeloid and lymphoid cell production in chimeric immunocompromised mice
US7273753B2 (en) 1996-08-02 2007-09-25 Center Of Blood Research Purification and uses of dendritic cells and monocytes
EP0973381B1 (en) 1997-04-09 2010-03-03 AMDL, Inc. Animal model for evaluation of vaccines
US6248721B1 (en) 1997-04-09 2001-06-19 Lung-Ji Chang Method of using mouse model for evaluation of HIV vaccines
CA2382383A1 (en) 1999-08-31 2001-03-08 Genencor International, Inc. Transgenic mammal capable of facilitating production of donor-specific functional immunity
US20030028911A1 (en) 1999-08-31 2003-02-06 Manley Huang Transgenic mammal capable of facilitating production of donor-specific functional immunity
EP1244807A1 (en) 1999-12-09 2002-10-02 Human Genome Sciences, Inc. Il-6 like polynucleotide
US6864061B2 (en) 2000-09-14 2005-03-08 Genetrol Biotherapeutics, Inc. Method for screening compounds for anti-inflammatory activity
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CA2453531A1 (en) * 2001-07-10 2003-01-23 Johnson & Johnson Research Pty Limited Methods for genetic modification of hematopoietic progenitor cells and uses of the modified cells
AU2002363322A1 (en) 2001-10-26 2003-05-19 Large Scale Biology Corporation Endothelial cell derived hemotopoietic growth factor
WO2003041495A1 (en) 2001-11-15 2003-05-22 Kirin Beer Kabushiki Kaisha Chimeric nonhuman animal
AU2003281309A1 (en) 2002-07-05 2004-01-23 Kirin Beer Kabushiki Kaisha Novel undifferentiated stem cells contained in cord blood, bone marrow, peripheral blood or the like
CN101250553A (zh) 2002-07-13 2008-08-27 上海医学遗传研究所 一种促人血小板生成素表达载体及其构建方法
EP1539946A4 (en) 2002-09-09 2006-03-15 California Inst Of Techn METHOD AND COMPOSITIONS FOR PRODUCING HUMANIZED MICE
EP1418185A1 (en) 2002-11-11 2004-05-12 Aventis Pharma Deutschland GmbH Use of EDG2 receptor in an animal model of heart failure
US7402728B2 (en) 2002-12-16 2008-07-22 Genentech, Inc. Transgenic mice expressing human CD20 and/or CD16
PL2767161T3 (pl) 2004-10-19 2018-09-28 Regeneron Pharmaceuticals, Inc. Sposób wytwarzania zwierzęcia homozygotycznego pod względem modyfikacji genetycznej
US7759541B2 (en) 2004-12-13 2010-07-20 Iti Life Sciences Transgenic animals for assessing drug metabolism and toxicity
GB2434578A (en) 2006-01-26 2007-08-01 Univ Basel Transgenic animals
AU2007244826B2 (en) 2006-04-25 2013-04-11 The Regents Of The University Of California Administration of growth factors for the treatment of CNS disorders
EP1878342A1 (en) 2006-07-13 2008-01-16 Institut Pasteur Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses
WO2008060360A2 (en) 2006-09-28 2008-05-22 Surmodics, Inc. Implantable medical device with apertures for delivery of bioactive agents
EP2088854A1 (en) 2006-12-05 2009-08-19 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Improved xenogenic immune system in a non-human mammal
EP2155873B1 (en) 2007-05-23 2016-11-09 Sangamo BioSciences, Inc. Methods and compositions for increased transgene expression
GB0718029D0 (en) 2007-09-14 2007-10-24 Iti Scotland Ltd Two step cluster deletion and humanisation
WO2009042917A1 (en) 2007-09-28 2009-04-02 The General Hospital Corporation Methods and compositions for antibody production
JP2011500005A (ja) * 2007-10-11 2011-01-06 ユニバーシティー ヘルス ネットワーク ヒト造血幹細胞の生着を増加させるためのＳＩＲＰα−ＣＤ４７相互作用の調節およびそのための化合物
EP2257250A2 (en) 2008-01-29 2010-12-08 Gilbert H. Kliman Drug delivery devices, kits and methods therefor
WO2011002721A1 (en) * 2009-06-29 2011-01-06 Leskov Ilya B Non-human mammal model of human hematopoietic cancer
RU2425880C2 (ru) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
WO2012051572A1 (en) 2010-10-15 2012-04-19 Massachusetts Institute Of Technology A humanized non-human mammal model of malaria and uses thereof
KR102714361B1 (ko) 2011-02-15 2024-10-11 리제너론 파마슈티칼스 인코포레이티드 인간화된 ｍ－ｃｓｆ 마우스
PL2663575T3 (pl) 2011-10-28 2015-03-31 Regeneron Pharma Humanizowane IL-6 i receptor IL-6
KR102473555B1 (ko) 2012-09-07 2022-12-05 예일 유니버시티 유전적으로 변형된 비-인간 동물 및 이것들의 사용 방법
IL311744B2 (en) 2012-11-05 2025-10-01 Regeneron Pharma Genetically modified non-human animals and methods of using them
PT4269430T (pt) 2013-09-23 2025-08-06 Regeneron Pharma Animais não-humanos com um gene humanizado de proteína reguladora de sinal
EP3138397B1 (en) 2013-10-15 2018-12-26 Regeneron Pharmaceuticals, Inc. Humanized il-15 animals
KR20250096864A (ko) 2014-05-19 2025-06-27 리제너론 파마슈티칼스 인코포레이티드 인간 epo를 발현하는 유전자 변형된 비-인간 동물
CN107896479B (zh) 2015-04-13 2021-07-13 再生元制药公司 人源化SIRPα-IL15敲入小鼠及其使用方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102725400A (zh) * 2009-06-29 2012-10-10 麻省理工学院 制造人源化的非人类哺乳动物的方法
US20110200982A1 (en) * 2009-10-06 2011-08-18 Regeneron Pharmaceuticals, Inc. Genetically modified mice and engraftment
WO2012040207A2 (en) * 2010-09-20 2012-03-29 Yale University HUMAM SIRPAα TRANSGENIC ANIMALS AND THEIR METHODS OF USE

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Engineering humanized mice for improved hematopoietic reconstitution;Adam C Drake et al.;《Cellular & Molecular Immunology》;20120319;第9卷;第221页Table3，第222页左栏第2段 *
Improving human hemato-lymphoidsystem mice by cytokine knock-in gene replacement;Tim Willinger et al.;《Trends in Immunology》;20110731;第32卷(第7期);第322页右栏第2段、第323页左栏第2段 *
人造血干细胞的免疫缺陷小鼠移植模型研究与应用;胡东等;《中国实验血液学杂志》;20041231;第12卷(第6期);第875-879页 *
免疫缺陷小鼠在白血病研究中的新进展;李仲霞等;《滨州医学院学报》;20081231;第31卷(第6期);第446-449页 *

Also Published As

Publication number Publication date
RU2017145913A (ru) 2019-02-19
KR102473555B1 (ko) 2022-12-05
AU2021240324A1 (en) 2021-10-28
AU2013312359A8 (en) 2019-08-15
JP7605789B2 (ja) 2024-12-24
CA2881468A1 (en) 2014-03-13
IL265570B (en) 2021-05-31
NZ704957A (en) 2018-05-25
CN113897398A (zh) 2022-01-07
AU2013312359B8 (en) 2019-08-15
SG11201500504RA (en) 2015-02-27
AU2019216625B2 (en) 2021-07-08
AU2013312359A1 (en) 2015-02-19
CN104955326B (zh) 2018-07-20
RU2642319C2 (ru) 2018-01-24
EP2892330A4 (en) 2016-07-27
KR102287541B1 (ko) 2021-08-10
PT2892330T (pt) 2023-02-17
JP6283031B2 (ja) 2018-02-21
JP2022105531A (ja) 2022-07-14
EP4193834C0 (en) 2025-05-14
MX364714B (es) 2019-05-06
US9820476B2 (en) 2017-11-21
RU2768282C2 (ru) 2022-03-23
JP2020168024A (ja) 2020-10-15
EP2892330A2 (en) 2015-07-15
CA2881468C (en) 2023-03-21
US20250072405A1 (en) 2025-03-06
JP7066785B2 (ja) 2022-05-13
DK2892330T3 (da) 2023-01-30
CN120718856A (zh) 2025-09-30
KR20150052274A (ko) 2015-05-13
US20200093105A1 (en) 2020-03-26
KR102340059B1 (ko) 2021-12-17
WO2014039782A2 (en) 2014-03-13
EP4606818A3 (en) 2025-10-22
KR20210099664A (ko) 2021-08-12
MX2015002983A (es) 2015-06-17
ES2938342T3 (es) 2023-04-10
JP2015529083A (ja) 2015-10-05
US20180020647A1 (en) 2018-01-25
US20150208622A1 (en) 2015-07-30
IL307969A (en) 2023-12-01
IL282472A (en) 2021-06-30
SG10201701759VA (en) 2017-04-27
ES3034290T3 (en) 2025-08-14
MX2019005251A (es) 2019-08-05
KR20230153500A (ko) 2023-11-06
CN113897398B (zh) 2025-07-08
US10433527B2 (en) 2019-10-08
IN2015DN02032A (enExample) 2015-08-14
JP2019110922A (ja) 2019-07-11
WO2014039782A3 (en) 2015-07-23
KR20210156846A (ko) 2021-12-27
CN104955326A (zh) 2015-09-30
HK1211176A1 (en) 2016-05-20
JP6517958B2 (ja) 2019-05-22
EP4193834B1 (en) 2025-05-14
IL236877A0 (en) 2015-03-31
IL265570A (en) 2019-05-30
KR20240045263A (ko) 2024-04-05
NZ746089A (en) 2020-05-29
US11026408B2 (en) 2021-06-08
RU2015112607A (ru) 2016-10-27
CN108782459A (zh) 2018-11-13
KR20220164808A (ko) 2022-12-13
US12127537B2 (en) 2024-10-29
KR20210044315A (ko) 2021-04-22
FI2892330T3 (fi) 2023-03-25
IL282472B1 (en) 2023-12-01
IL282472B2 (en) 2024-04-01
IL307969B1 (en) 2025-10-01
KR102594390B1 (ko) 2023-10-27
US20190082663A1 (en) 2019-03-21
EP4193834A1 (en) 2023-06-14
RU2017145913A3 (enExample) 2021-08-16
KR102645622B1 (ko) 2024-03-11
AU2013312359B2 (en) 2019-05-23
EP4606818A2 (en) 2025-08-27
NZ741951A (en) 2020-04-24
JP6732998B2 (ja) 2020-07-29
KR102241962B1 (ko) 2021-04-20
AU2021240324B2 (en) 2024-02-22
MX385035B (es) 2025-03-14
US20210368752A1 (en) 2021-12-02
EP2892330B1 (en) 2022-11-23
JP2018088925A (ja) 2018-06-14
AU2019216625A1 (en) 2019-09-05

Similar Documents

Publication Publication Date Title
US12127537B2 (en) Genetically modified non-human animals and methods of use thereof
HK40095010B (en) Methods of using genetically modified mice
HK40095010A (en) Methods of using genetically modified mice
HK1211176B (en) Genetically modified mice and methods of use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant